HA-00495 / Hexagon Bio - LARVOL DELTA

HA-00495: A development candidate ADC featuring a novel protein translation inhibitor payload with broad efficacy and a favorable non human primate safety profile (AACR 2026) - "In vivo, ADCs generated using anti-TROP2 (sacituzumab) and anti-HER2 (trastuzumab) antibodies demonstrated deep and durable antitumor activity in bladder, gastric, breast and lung cancer models, including models with known resistance to topoisomerase inhibitor-based ADCs. We will present the clinical observations, clinical pathology, histopathology and key findings from these studies.In summary, we have identified a novel protein translation inhibitor payload class for ADCs that demonstrates strong efficacy, activity in resistance settings and a favorable NHP safety profile. These results support the potential of HA-00495 to address critical gaps in current ADC therapies and development activities for this candidate are now underway."

ADC • Clinical • Bladder Cancer • Breast Cancer • Lung Cancer • Oncology • Solid Tumor